INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	Approved for use through 07/31/2012.
Application Number	10/594,127
Confirmation Number	8975
Filing Date	September 25, 2006
First Named Inventor	Akio SUGIHARA
Art Unit	1625
Examiner Name	Niloofar RAHMANI
Attorney Docket Number	Q97391

U.S. PATENTS						
Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Cite No Publication Number Kind Code Publication Date Applicant of rised Populary When				Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸

NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁶		
	1.	Office Action issued on April 28, 2011 by the State of Israel in the corresponding Israeli Patent Application No. 183877	Υ		

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kin Codes of USPTO Patient Documents at www.USPTO.GOV or MPEP.901.04. 2 Either office in this issued the document, by the two-letter code (WIPO Standard at 785). 3 For Japones period focuments, the indication of the year of the region of the Empirer or patient percent be sensited by the percent in the patient of t